Annals of Hematology

, Volume 92, Issue 1, pp 125–127

Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation

  • R. Ordemann
  • J. Stöhlmacher
  • B. Beuthien-Baumann
  • I. Platzek
  • J. van den Hoff
  • F. Kroschinsky
  • J. M. Middeke
  • U. Platzbecker
  • C. Zietz
  • M. Bornhäuser
  • G. Ehninger
Letter to the Editor

DOI: 10.1007/s00277-012-1524-0

Cite this article as:
Ordemann, R., Stöhlmacher, J., Beuthien-Baumann, B. et al. Ann Hematol (2013) 92: 125. doi:10.1007/s00277-012-1524-0

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • R. Ordemann
    • 1
  • J. Stöhlmacher
    • 1
  • B. Beuthien-Baumann
    • 2
  • I. Platzek
    • 2
  • J. van den Hoff
    • 3
  • F. Kroschinsky
    • 1
  • J. M. Middeke
    • 1
  • U. Platzbecker
    • 1
  • C. Zietz
    • 4
  • M. Bornhäuser
    • 1
  • G. Ehninger
    • 1
  1. 1.Medical Clinic and Policlinic IUniversity HospitalDresdenGermany
  2. 2.Department of Radiation OncologyUniversity HospitalDresdenGermany
  3. 3.PET CenterInstitute of Radiopharmacy, Helmholtz-Zentrum Dresden-RossendorfDresdenGermany
  4. 4.Department of PathologyUniversity HospitalDresdenGermany